tert-butyl 4-((propylamino)methyl)piperidine-1-carboxylate | 1268465-03-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-((propylamino)methyl)piperidine-1-carboxylate
• 英文别名: tert-butyl 4-(propylaminomethyl)piperidine-1-carboxylate
• CAS: 1268465-03-7
• 化学式: C₁₄H₂₈N₂O₂
• 分子量: 256.389
• InChiKey: HBOHJSPVVBSKRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-叔丁氧羰基-4-氨甲基哌啶 在 20 wt% Pd(OH)2/C 氢气 、 sodium hydride 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 20.0h， 生成 tert-butyl 4-((propylamino)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
  [FR] BENZOAZÉPINES SUBSTITUÉES COMME MODULATEURS DES RÉCEPTEURS DE TYPE TOLL

  摘要：

  公开号：

  WO2011022508A3

文献信息

• SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
  申请人：Howbert James Jeffry

  公开号：US20110092485A1

  公开（公告）日：2011-04-21

  Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

  提供的是用于调节Toll样受体(TLR7和/或TLR8)信号传导的组合物和方法。这些组合物和方法在治疗或预防疾病方面具有用途，包括癌症、自身免疫性疾病、传染病、炎症性疾病、移植排斥以及移植物抗宿主病。
• Substituted benzoazepines as toll-like receptor modulators
  申请人：Howbert James Jeffry

  公开号：US08691809B2

  公开（公告）日：2014-04-08

  Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

  提供的是用于调节Toll样受体TLR7和/或TLR8信号传导的组合物和方法。这些组合物和方法在治疗或预防疾病方面有用，包括癌症、自身免疫性疾病、传染性疾病、炎症性疾病、移植排斥和移植物抗宿主病。
• Substituted Benzoazepines as Toll-Like Receptor Modulators
  申请人：Array BioPharma, Inc.

  公开号：US20140234376A1

  公开（公告）日：2014-08-21

  Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

  提供了用于调节Toll样受体(TLR7和/或TLR8)信号的组合物和方法。这些组合物和方法在治疗或预防疾病方面具有用途，包括癌症、自身免疫性疾病、感染性疾病、炎症性疾病、移植排斥和移植物抗宿主病。
• [EN] COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE<br/>[FR] COMPOSÉS ET MÉTHODES POUR LA DÉGRADATION CIBLÉE DU RÉCEPTEUR DES ANDROGÈNES ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2022098544A1

  公开（公告）日：2022-05-12

  Bifunctional compounds, which find utility as modulators of androgen receptor (AR), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds AR, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure..

  本文描述了具有雄激素受体（AR）调节剂作用的双功能化合物。具体而言，本公开的双功能化合物在一端包含结合到 cereblon E3 泛素连接酶的一个部分，在另一端包含结合 AR 的一个部分，从而使目标蛋白质靠近泛素连接酶，以促进目标蛋白质的降解（和抑制）。本公开的双功能化合物表现出与目标蛋白质的降解/抑制相关的广泛药理活性。使用本公开的化合物和组合物治疗或预防由于目标蛋白质异常调节而导致的疾病或障碍。
• INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
  申请人：Syros Pharmaceuticals, Inc.

  公开号：US20190330218A1

  公开（公告）日：2019-10-31

  The present invention provides novel compounds described herein, such as of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.